Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
PR Newswire, San Diego, October 8, 2020 - Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston,...
Viracta Therapeutics, Inc. ("Viracta" or the "Company"), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Roger J. Pomerantz, MD, FACP, as...
Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of...
Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, today announced that Mark A. McCamish, MD, PhD, has joined Viracta as a...
Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that Roger J. Pomerantz, MD, FACP, has been appointed to its Board of Directors....